Literature DB >> 18161743

Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Raymond T Chung1, Michael Gale, Stephen J Polyak, Stanley M Lemon, T Jake Liang, Jay H Hoofnagle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18161743      PMCID： PMC2799164          DOI： 10.1002/hep.22070

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  70 in total

1.  Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1.

Authors:  Francois H T Duong; Verena Christen; Jan Martin Berke; Sabina Hernandez Penna; Darius Moradpour; Markus H Heim
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.

Authors:  Takanobu Kato; Tomoko Date; Michiko Miyamoto; Masaya Sugiyama; Yasuhito Tanaka; Etsuro Orito; Tomoyoshi Ohno; Kanji Sugihara; Izumi Hasegawa; Kei Fujiwara; Kiyoaki Ito; Atsushi Ozasa; Masashi Mizokami; Takaji Wakita
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

4.  Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients.

Authors:  Maria W Smith; Kathie-Anne Walters; Marcus J Korth; Matthew Fitzgibbon; Sean Proll; Jill C Thompson; Matthew M Yeh; Margaret C Shuhart; Jeffrey C Furlong; Paula P Cox; David L Thomas; John D Phillips; James P Kushner; Nelson Fausto; Robert L Carithers; Michael G Katze
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

Review 5.  Host genetic determinants in hepatitis C virus infection.

Authors:  L J Yee
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

6.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

7.  Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.

Authors:  Yoko Tanabe; Naoya Sakamoto; Nobuyuki Enomoto; Masayuki Kurosaki; Eri Ueda; Shinya Maekawa; Tsuyoshi Yamashiro; Mina Nakagawa; Cheng-Hsin Chen; Nobuhiko Kanazawa; Sei Kakinuma; Mamoru Watanabe
Journal:  J Infect Dis       Date:  2004-03-16       Impact factor: 5.226

8.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

9.  A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame.

Authors:  Ermei Yao; John E Tavis
Journal:  Virol J       Date:  2005-12-01       Impact factor: 4.099

10.  Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

Authors:  Yasuhiro Asahina; Namiki Izumi; Nobuyuki Enomoto; Masakatsu Uchihara; Masayuki Kurosaki; Yuko Onuki; Yuki Nishimura; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Takatoshi Kitamura; Shozo Miyake
Journal:  J Hepatol       Date:  2005-10       Impact factor: 25.083
View more
  28 in total

1.  Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Authors:  Jan Paeshuyse; Inge Vliegen; Lotte Coelmont; Pieter Leyssen; Oriana Tabarrini; Piet Herdewijn; Harald Mittendorfer; Johnny Easmon; Violetta Cecchetti; Ralf Bartenschlager; Gerhard Puerstinger; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 2.  The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.

Authors:  Virginia Clark; David R Nelson
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

Review 3.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

4.  Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.

Authors:  Keanan McGonigle; Tess Carley; Clarissa Hoff
Journal:  J Racial Ethn Health Disparities       Date:  2017-12-29

Review 5.  Environmental triggers of thyroiditis: hepatitis C and interferon-α.

Authors:  F Menconi; A Hasham; Y Tomer
Journal:  J Endocrinol Invest       Date:  2010-02-28       Impact factor: 4.256

6.  Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.

Authors:  Noy Ashkenazy; Carol L Karp; Gaofeng Wang; Carolina Mercado Acosta; Anat Galor
Journal:  Cornea       Date:  2017-04       Impact factor: 2.651

Review 7.  Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.

Authors:  Kaartik Soota; Benedict Maliakkal
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

8.  Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  Tania Mara Welzel; Timothy R Morgan; Herbert L Bonkovsky; Deepa Naishadham; Ruth M Pfeiffer; Elizabeth C Wright; Amy A Hutchinson; Andrew T Crenshaw; Arman Bashirova; Mary Carrington; Myhanh Dotrang; Richard K Sterling; Karen L Lindsay; Robert J Fontana; William M Lee; Adrian M Di Bisceglie; Marc G Ghany; David R Gretch; Stephen J Chanock; Raymond T Chung; Thomas R O'Brien
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 9.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

10.  Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.

Authors:  Lotte Coelmont; Suzanne Kaptein; Jan Paeshuyse; Inge Vliegen; Jean-Maurice Dumont; Grégoire Vuagniaux; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.